{"id":"W2883546793","doi":"10.1002/jcph.1107","title":"Cardiovascular Safety of the β<sub>3</sub>‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial","year":2018,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Allergan; Astellas Pharma Global Development; Astellas Foundation for Research on Metabolic Disorders; Ipsen; Pfizer","keywords":"Mirabegron; Solifenacin; Medicine; Placebo; Overactive bladder; Combination therapy; Urology; Internal medicine; Pharmacology; Anesthesia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001560206,0.0006979692,0.001435294,0.0001892545,0.0002340169,0.0007943356,0.0003096118,0.0009129259,0.004121114],"category_scores_gemma":[0.0009024539,0.000268647,0.001323515,0.0001802477,0.0003659731,0.0004064084,0.0003154814,0.001592978,0.000494657],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004158062,"about_ca_system_score_gemma":0.0006601794,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002437452,"about_ca_topic_score_gemma":0.0006414023,"domain_scores_codex":[0.9994376,0.0003454121,0.00003428536,0.00005422748,0.00005196974,0.00007644646],"domain_scores_gemma":[0.9994277,0.0001424415,0.0001528957,0.00003142134,0.0000495251,0.0001958972],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9289775,0.003120311,0.0040404,0.001097894,0.002102894,0.0001237263,0.00007175473,0.000592573,0.00949902,0.000294871,0.002349546,0.04772944],"study_design_scores_gemma":[0.7002193,0.2590592,0.02607248,0.0003215829,0.003013072,0.0004828624,0.00008668622,0.00134773,0.003393578,0.0006311645,0.005323957,0.00004834326],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981856,0.01209396,0.0003842567,0.0008839855,0.0002629849,0.0003942642,0.0007021188,0.00005210192,0.00337018],"genre_scores_gemma":[0.9926596,0.002878524,0.0005776847,0.0009800777,0.0003136773,0.0004549446,0.001072026,0.00001053366,0.001052903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004121114,"threshold_uncertainty_score":0.01378655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.063444621870896,"score_gpt":0.4039625429456552,"score_spread":0.3405179210747592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}